Darifencacin (darifenacin) News
Incontinence: Don’t Suffer In Silence
Incontinence affects nearly half of all women at some point in their lives, but it is a problem that many suffer from in silence. Some women are afraid to talk to their health care providers about it, but there is a place where...
New drug for overactive bladder lacks cognitive side effects
Darifenacin, a selective muscarinic M3 receptor antagonist approved last month for the treatment of overactive bladder, doesn't affect cognition in the elderly at clinically effective doses, Richard B. Lipton, M.D., reported at...
FDA Approves Enablex (Darifenacin) for Treatment of Overactive Bladder
Novartis Pharmaceuticals Corporation announced that the U.S. Food and Drug Administration (FDA) has approved Enablex® (darifenacin) extended-release tablets (7.5mg and 15mg) for the treatment of overactive bladder (OAB) with...
International Approvals: Canada, EU, Israel, Norway, Iceland
Anagrelide HCl has been approved in the European Union (EU) as a second-line therapy for essential thrombocythemia.
Darifenacin substantially improves quality of life for people with overactive bladder symptoms
Darifenacin significantly improves important emotional, physical and social limitations associated with overactive bladder symptoms.